Since the early 2000s, several monoclonal antibodies have been approved: omalizumab (anti-IgE) was first approved in 2003 for allergic asthma (D’Amato, 2003), followed by IL-5 pathway inhibitors (mepolizumab, reslizumab, and benralizumab) for eosinophilic asthma (Lombardi et al., 2024; Ridolo et al., 2020) and, more recently, dupilumab (anti-IL-4 receptor α) (Shirley, 2017) and tezepelumab (anti-TSLP) for broad T2 inflammatory conditions (Ridolo et al., 2020). This evidence concerns the gene IGHE and allergic asthma.